Cradle, which uses AI to help design and engineer proteins faster and more cost-effectively, raised a $24M Series A led by Index Ventures
Context & Ripple Effects
Cradle’s financing arrives as AI is being applied across the life-sciences R&D stack: laboratory-automation software targets experimental workflows, while Inceptive raised capital for an AI platform for mRNA molecule design. Cradle focuses that investment thesis on protein engineering, where software must prove useful to scientific teams rather than merely generate outputs.
The later $73M Series B shows that Cradle’s initial round became a platform for a larger SaaS expansion, making this Series A an early marker of investor appetite for commercializable AI biology tools.
First-order effects
- Cradle gains capital to develop and deploy its protein-design and engineering software, with Index Ventures becoming a key backer.
- The round gives prospective biotech and pharmaceutical users a better-capitalized vendor for AI-assisted protein engineering.
Second-order effects
- Other AI-biology companies face more pressure to distinguish their modality, workflow integration, or business model as Cradle funds product development and customer adoption.
- The investment reinforces demand for the surrounding research-software layer, where companies such as Benchling have already raised funding for biotech data-management software.
Third-order effects
- If AI protein-design vendors can establish recurring software use in R&D, life-science software may shift from recording and automating experiments toward helping determine what scientists test next.
- Capital is likely to concentrate around AI-biology platforms that can pair model capabilities with usable research workflows; whether that creates durable category leaders depends on adoption and scientific validation.
The trend: AI in life sciences is moving from general lab software toward specialized systems intended to influence molecular design decisions and become recurring R&D infrastructure.